## Seq List.ST25 SEQUENCE LISTING

```
Yeda Research and Development Co. Ltd. at the Weizmann
<110>
       Institute of Science
       Diastereomeric Peptides Useful As Inhibitors of Membrane Protein
<120>
       Assembly
<130>
       YEDA/038 PCT
<150>
       US 60/530,899
       2003-12-22
<151>
<160>
       29
<170>
       PatentIn version 3.3
<210>
       36
<211>
<212>
       PRT
       Artificial sequence
<213>
<220>
<223>
       Synthetic peptide
<400>
       1
Tyr Thr Ser Leu Ile His Ser Leu Ile Glu Glu Ser Gln Asn Gln Gln
Glu Lys Asn Glu Gln Glu Leu Leu Glu Leu Asp Lys Trp Ala Ser Leu 20 25 30
Trp Asn Trp Phe 35
<210>
<211>
       36
<212>
        PRT
       Artificial sequence
<213>
<220>
        Synthetic peptide
<223>
<220>
<221>
<222>
<223>
        MISC_FEATURE
        (12)..(12)
        D-Ser
<220>
<221>
<222>
        MISC_FEATURE
        (13)..(13)
<223>
        D-Gln
<400>
Tyr Thr Ser Leu Ile His Ser Leu Ile Glu Glu Ser Gln Asn Gln Gln 1 10 15
```

Glu Lys Asn Glu Gln Glu Leu Leu Glu Leu Asp Lys Trp Ala Ser Leu

The state of the s

```
Trp Asn Trp Phe 35
<210>
<211>
        36
<212>
        PRT
        Artificial sequence
<213>
<220>
<223> Synthetic peptide
<220>
<221>
<222>
<223>
        MISC_FEATURE (32)..(32)
        D-Leu
<220>
<221>
<222>
        MISC_FEATURE
        (33)..(33)
       D-Trp
<223>
<400> 3
Tyr Thr Ser Leu Ile His Ser Leu Ile Glu Glu Ser Gln Asn Gln Gln 10 15
Glu Lys Asn Glu Gln Glu Leu Leu Glu Leu Asp Lys Trp Ala Ser Leu 20 25 30
Trp Asn Trp Phe 35
<210>
<211>
        33
        PRT
<213> Artificial sequence
<220>
<223>
        Synthetic peptide
<400> 4
Ala Val Gly Ile Gly Ala Leu Phe Leu Gly Phe Leu Gly Ala Ala Gly 1 \hspace{1cm} 5 \hspace{1cm} 10 \hspace{1cm} 15
Ser Thr Met Gly Ala Arg Ser Met Thr Leu Thr Val Gln Ala Arg Gln 20 25 30
Leu
        5
33
<210>
<211>
<212>
        PRT
<213>
        Artificial sequence
<220>
<223> Synthetic peptide
```

```
<220>
<221>
<222>
<223>
       MISC_FEATURE
        (4)..(4)
D-Ile
<220>
<221>
<222>
        MISC_FEATURE
        (8)..(8)
<223> D-Phe
<220>
<221> MISC_FEATURE <222> (11)..(11)
        D-Phe
<223>
<220>
        MISC_FEATURE
(14)..(14)
D-Ala
<221>
<222>
<223>
<400> 5
Ala Val Gly Ile Gly Ala Leu Phe Leu Gly Phe Leu Gly Ala Ala Gly 10 15
Ser Thr Met Gly Ala Arg Ser Met Thr Leu Thr Val Gln Ala Arg Gln 20 25 30
 Leu
         6
33
 <210>
 <211>
<212>
         PRT
         Artificial sequence
 <21.3>
 <220>
 <223> Synthetic peptide
 <220>
 <221>
<222>
<223>
         MISC_FEATURE (8)..(8)
         D-Phe
 <220>
 <221>
<222>
         MISC_FEATURE
          (11)..(11)
 <223>
          D-Phe
 <400> 6
 Ala Val Gly Ile Gly Ala Leu Phe Leu Gly Phe Leu Gly Ala Ala Gly
10 15
 Ser Thr Met Gly Ala Arg Ser Met Thr Leu Thr Val Gln Ala Arg Gln 20 25 30
```

Leu

Seq List.ST25 <211> <212> PRT Artificial sequence <213> <220> <223> Synthetic peptide <220> <221> <222> <223> MISC\_FEATURE (8)..(8) D-Phe <220> <221> <222> <223> MISC\_FEATURE (11)..(11) D-Phe <220> <221> <222> MISC\_FEATURE (21)..(21) <223> D-Ala <220> <221> <222> MISC\_FEATURE (26)..(26)<223> D-Leu <400> Ala Val Gly Ile Gly Ala Leu Phe Leu Gly Phe Leu Gly Ala Ala Gly
1 10 15 Ser Thr Met Gly Ala Arg Ser Met Thr Leu Thr Val Gln Ala Arg Gln 20 25 30 Leu 8 15 <210> <211> <212> PRT Artificial sequence <213> <220> <223> Synthetic peptide <400> 8 Ile Thr Leu Ile Ile Phe Gly Val Met Ala Gly Val Ile Gly Thr <210> **1**7 <211> <212> PRT Artificial sequence <213> <220> Synthetic peptide <223> <400> Lys Ile Thr Leu Ile Ile Phe Gly Val Met Ala Gly Val Ile Gly 10

Page 4

Thr <210> 10 19 <211> <212> PRT Artificial sequence <213> <220> <223> Synthetic peptide <400> 10 Lys Lys Ile Thr Leu Ile Ile Phe Gly Val Met Ala Gly Val Ile Gly 1 10 15 Thr Lys Lys 11 15 <210> <211> <212> PRT Artificial sequence <213> <220> <223> Synthetic peptide <220> <221> MISC\_FEATURE <222> (8)..(8) <223> D-Val <220> MISC\_FEATURE (12)..(12) D-Val <221> <222> <223> <400> 11 Ile Thr Leu Ile Ile Phe Gly Val Met Ala Gly Val Ile Gly Thr 10 15<210> <211> 12 17 <212> PRT Artificial sequence <213> <220> Synthetic peptide <223> <220> <221> <222> <223> MISC\_FEATURE (10)..(10) D-Val <220> <221> <222> 223> MISC\_FEATURE (14)..(14) D-Val

Page 5

```
<400> 12
Lys Lys Ile Thr Leu Ile Ile Phe Gly Val Met Ala Gly Val Ile Gly 10 15
Thr
<210>
        13
<211>
<212>
        19
        PRT
       Artificial sequence
<213>
<220>
<223> Synthetic peptide
<220>
<221>
        MISC_FEATURE (10)..(10)
<222>
<223>
        D-Val
<220>
        MISC_FEATURE
(14)..(14)
D-Val
<221>
<222>
<223>
<400> 13
Lys Lys Ile Thr Leu Ile Ile Phe Gly Val Met Ala Gly Val Ile Gly 10 15
Thr Lys Lys
<210>
<211>
         15
 <212>
         PRT
 <213> Artificial sequence
 <220>
 <223> Synthetic peptide
 <220>
 <221>
<222>
<223>
         MISC_FEATURE (5)..(5) D-Ile
 <220>
<221>
<222>
         MISC_FEATURE (13)..(13)
         D-Ile
 <223>
 <400>
 Ile Thr Leu Ile Ile Phe Gly Val Met Ala Gly Val Ile Gly Thr 1 10 15
          15
17
 <210>
```

<211>

PRT

Artificial sequence

Page 6

```
<220>
<223> Synthetic peptide
<220>
<221>
<222>
<223>
       MISC_FEATURE
        (7)..(7)
D-Ile
<220>
<221> MISC_FEATURE
<222> (15)..(15)
<223> D-Ile
<400> 15
Lys Lys Ile Thr Leu Ile Ile Phe Gly Val Met Ala Gly Val Ile Gly 10 15
Thr
<210>
        16
<211>
<212>
        19
        PRT
        Artificial sequence
<220>
<223> Synthetic peptide
<220>
       MISC_FEATURE
(7)..(7)
D-Ile
<221>
<222>
<223>
<220>
<221>
        MISC_FEATURE
<222>
         (15)..(15)
<223>
        D-Ile
<400> 16
Lys Lys Ile Thr Leu Ile Ile Phe Gly Val Met Ala Gly Val Ile Gly 1 10 15
Thr Lys Lys
        17
32
<210>
<211>
<212>
        PRT
        Artificial sequence
<213>
<220>
<223>
       Synthetic peptide
<220>
<221>
<222>
<222>
        MISC_FEATURE
       (13)..(13)
D-Val
```

```
<220>
 <221>
<222>
         MISC_FEATURE
        (17)..(17)
D-Val
 <223>
 <400> 17
 Phe Ser Glu Pro Glu Ile Thr Leu Ile Ile Phe Gly Val Met Ala Gly 10 15
. Val Ile Gly Thr Ile Leu Leu Ile Ser Tyr Gly Ile Arg Arg Leu Ile 20 25 30
 <210>
         35
 <211>
 <212>
         PRT
 <213>
        Artificial sequence
 <220>
<223> Synthetic peptide
 <220>
<221>
         MISC_FEATURE
 <222>
         (16)..(16)
D-Val
 <223>
 <220>
 <221>
<222>
         MISC_FEATURE
         (20)..(20)
D-Val
 <223>
 <400> 18
 Lys Lys Lys Phe Ser Glu Pro Glu Ile Thr Leu Ile Ile Phe Gly Val 10 	 10 	 15
 Met Ala Gly Val Ile Gly Thr Ile Leu Leu Ile Ser Tyr Gly Ile Arg
20 25 30
 Arg Leu Ile
35
  <210>
          19
          32
  <211>
  <212>
         PRT
  <213>
        Artificial sequence
  <220>
  <223> Synthetic peptide
  <220>
         MISC_FEATURE
(10)..(10)
D-Ile
  <221>
<222>
  <223>
  <220>
  <221>
<222>
          MISC_FEATURE (18)..(18)
  <223>
          D-Ile
         19
```

PCT/IL2004/001157 WO 2005/060350

Seq List.ST25

Phe Ser Glu Pro Glu Ile Thr Leu Ile Ile Phe Gly Val Met Ala Gly 10 15

Val Ile Gly Thr Ile Leu Leu Ile Ser Tyr Gly Ile Arg Arg Leu Ile 20 25 30

<210> 20

<211> <212> 16

PRT

Artificial sequence

<220>

<223> Synthetic peptide

<400>

Met Val Leu Gly Val Phe Ala Leu Leu Gln Leu Ile Ser Gly Ser Leu 1 10 15

21 21 <210>

<211> <212>

PRT

Artificial sequence

<220>

<223> Synthetic peptide

<400> 21

Lys Lys Lys Met Val Leu Gly Val Phe Ala Leu Leu Gln Leu Ile Ser 1 10 15

Gly Ser Leu Lys Lys 20

<210> 22

16

<211> <212> PRT

Artificial sequence <213>

<220>

<223> Synthetic peptide

<220>

MISC\_FEATURE

<221> <222> (10)..(10) D-Gln

<223>

<220>

MISC\_FEATURE (15)..(15) <221>

<222>

<223> D-Ser

<400>

Met Val Leu Gly Val Phe Ala Leu Leu Gln Leu Ile Ser Gly Ser Leu 10 15

```
<212> PRT
<213> Artificial sequence
<220>
<223> Synthetic peptide
<220>
<221>
<222>
        MISC_FEATURE
        (13)..(13)
D-Gln
<223>
<220>
        MISC_FEATURE (18)..(18)
<221>
<222>
<223> D-Ser
<400> 23
Lys Lys Lys Met Val Leu Gly Val Phe Ala Leu Leu Gln Leu Ile Ser 10 \ 15
Gly Ser Leu Lys Lys
20
<210> 24
<211> 8
<212> PRT
        Artificial sequence
<223> Synthetic peptide
 <400> 24
Ala Val Gly Ile Gly Ala Leu Phe 1
         25
17
 <210>
 <211>
 <212>
         PRT
         Artificial sequence
 <213>
 <220>
 <223> Synthetic peptide
 <220>
         MISC_FEATURE
 <221>
 <222> (5)..(5)
<223> D-Ala
 <220>
<221>
<222>
<223>
         MISC_FEATURE
(6)..(6)
D-Glu
 <220>
 <221> MISC_FEATURE <222> (7)..(7)
 <222> (7)..(7)
<223> D-Ala
 <220>
      > MISC_FEATURE
      !> (8)..(8)
```

```
<223> D-Ala
<220>
        MISC_FEATURE (11)..(11)
<221>
<222>
        D-Ala
<220>
<221>
<222>
        MISC_FEATURE
        (15)..(15)
<223>
        D-Ala
<220>
        MISC_FEATURE
<221>
<222>
<223>
        (16)..(16)
D-Ala
<220>
<221>
<222>
        MISC_FEATURE
 <222> (17)..(17)
<223> D-Ala
 <400> 25
Lys Lys Ile Thr Ala Gly Ala Ala Gly Val Ala Ala Gly Val Ala Ala
1 10 15
 Ala
 <210>
         26
 <211>
        34
 <212>
        PRT
        Artificial sequence
 <213>
 <220>
 <223> Synthetic peptide
 <400> 26
 Trp Met Glu Trp Asp Arg Glu Ile Asn Asn Tyr Thr Ser Leu Ile His 1 10 15
 Ser Leu Ile Glu Glu Ser Gln Asn Gln Gln Glu Lys Asn Glu Gln Glu
20 25 30
 Leu Leu
 <210>
 <211> 13
<212> PRT
        Artificial sequence
 <213>
 <220>
 <223>
        Synthetic peptide
 <400> 27
 Ala Val Gly Ile Gly Ala Leu Phe Leu Gly Phe Leu Gly
1 10
```

## Seq List.ST25

<210> 33

PRT

Artificial sequence

<220>

<223> Synthetic peptide

<400> 28

Phe Phe Gly Ala Val Ile Gly Thr Ile Ala Leu Gly Val Ala Thr Ser 1 10 15

Ala Gln Ile Thr Ala Gly Ile Ala Leu Ala Glu Ala Arg Glu Ala Lys 20 25 30

Arg

<210>

21

Artificial sequence

<220> <223> Synthetic peptide

<400> 29

Lys Lys Lys Met Val Leu Gly Val Phe Ala Leu Leu Phe Leu Ile Gly  $1 \hspace{1cm} 5 \hspace{1cm} 10 \hspace{1cm} 15$ 

Gly Ser Leu Lys Lys 20